Literature DB >> 1356648

Active cell death in hormone-dependent tissues.

M P Tenniswood1, R S Guenette, J Lakins, M Mooibroek, P Wong, J E Welsh.   

Abstract

Active cell death (ACD) in hormone-dependent tissues such as the prostate and mammary gland is readily induced by hormone ablation and by treatment with anti-androgens or anti-estrogens, calcium channel agonists and TGF beta. These agents induce a variety of genes within the hormone-dependent epithelial cells including TRPM-2, transglutaminase, poly(ADP-ribose) polymerase, Hsp27 and several other unidentified genes. Not all epithelial cells in the glands are equally sensitive to the induction of ACD. In the prostate, the secretory epithelial cells that are sensitive to hormone ablation are localized in the distal region of the prostatic ducts, and are in direct contact with the neighboring stroma. In contrast, the epithelial cells in the proximal regions of the ducts are more resistant to hormone ablation, probably because the permissive effects of the stroma are attenuated by the presence of the basal epithelial cells, which are intercalated between the epithelium and stroma. The underlying biology of ACD in prostate and mammary glands, and its relevance to hormone resistance, is discussed in this review.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356648     DOI: 10.1007/bf00048064

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  228 in total

1.  Study on the growth limiting mechanism in the rat ventral prostate.

Authors:  J Müntzing; G P Murphy
Journal:  Proc Soc Exp Biol Med       Date:  1977-03

2.  Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration.

Authors:  H F English; N Kyprianou; J T Isaacs
Journal:  Prostate       Date:  1989       Impact factor: 4.104

3.  Filamentous cross-bridges link intermediate filaments to the nuclear pore complexes.

Authors:  M Carmo-Fonseca; A J Cidadão; J F David-Ferreira
Journal:  Eur J Cell Biol       Date:  1988-02       Impact factor: 4.492

Review 4.  Role of Ca2+ in toxic cell killing.

Authors:  S Orrenius; D J McConkey; G Bellomo; P Nicotera
Journal:  Trends Pharmacol Sci       Date:  1989-07       Impact factor: 14.819

5.  Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats.

Authors:  S N Freeman; P S Rennie; J Chao; L R Lund; P A Andreasen
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

6.  Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death.

Authors:  N Kyprianou; H F English; J T Isaacs
Journal:  Prostate       Date:  1988       Impact factor: 4.104

7.  Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.

Authors:  F C Ramaekers; A P Verhagen; J T Isaacs; W F Feitz; O Moesker; G Schaart; J A Schalken; G P Vooijs
Journal:  Prostate       Date:  1989       Impact factor: 4.104

8.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis.

Authors:  S M Laster; J G Wood; L R Gooding
Journal:  J Immunol       Date:  1988-10-15       Impact factor: 5.422

9.  Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.

Authors:  F Labrie; A Dupont; A Belanger; R Lachance
Journal:  J Urol       Date:  1987-10       Impact factor: 7.450

10.  Epithelium-dependent extracellular matrix synthesis in transforming growth factor-beta 1-growth-inhibited mouse mammary gland.

Authors:  G B Silberstein; P Strickland; S Coleman; C W Daniel
Journal:  J Cell Biol       Date:  1990-06       Impact factor: 10.539

View more
  30 in total

Review 1.  Hormonal regulation of physiological cell turnover and apoptosis.

Authors:  R D Medh; E B Thompson
Journal:  Cell Tissue Res       Date:  2000-07       Impact factor: 5.249

2.  Overexpression of clusterin in human breast carcinoma.

Authors:  M Redondo; E Villar; J Torres-Muñoz; T Tellez; M Morell; C K Petito
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 4.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 5.  Communication between the cell membrane and the nucleus: role of protein compartmentalization.

Authors:  S A Lelièvre; M J Bissell
Journal:  J Cell Biochem Suppl       Date:  1998

6.  Cardiovascular medication use and risk for colorectal cancer.

Authors:  Denise M Boudreau; Elizabeth Koehler; Stephen J Rulyak; Sebastien Haneuse; Robert Harrison; Margaret T Mandelson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-10-28       Impact factor: 4.254

7.  Expression of clusterin (testosterone-repressed prostate message-2) mRNA during growth and regeneration of rat liver.

Authors:  W Bursch; T Gleeson; L Kleine; M Tenniswood
Journal:  Arch Toxicol       Date:  1995       Impact factor: 5.153

8.  Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status.

Authors:  K Nesaretnam; R Stephen; R Dils; P Darbre
Journal:  Lipids       Date:  1998-05       Impact factor: 1.880

9.  Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice.

Authors:  R C Bargou; C Wagener; K Bommert; M Y Mapara; P T Daniel; W Arnold; M Dietel; H Guski; A Feller; H D Royer; B Dörken
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.